Skip to content
News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Xpovio-selinexor
September 22, 2023
Xpovio (selinexor) in Endometrial Cancer
Dr. C H Weaver MD
August 3, 2022
Selinexor/Jalafi Combination Shows Early Activity in Myelofibrosis
Dr. C H Weaver MD
December 26, 2020
Xpovio – Selinexor Approved by FDA for the Treatment of Multiple Myeloma
Dr. C H Weaver MD
June 8, 2019
Certain Patients With Glioblastoma Appear to Respond to Selinexor
Dr. C H Weaver MD
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
